A Comprehensive Analysis Examining the Role of Genetic Influences on Psychotropic Medication Response in Children.
Gene tests for CYP2D6, CYP2C19, and ABCB1 can flag which kids are at risk for toxic or failed psychotropic response.
01Research in Context
What this study did
Singh et al. (2025) looked at every paper that linked genes to how kids react to psychotropic meds. They pulled studies on children with autism, ADHD, and other diagnoses.
The team focused on three gene families: CYP2D6, CYP2C19, and ABCB1. These genes control how fast the body breaks down common pills like risperidone and fluoxetine.
What they found
The review shows that certain gene variants change drug levels in the blood. Kids with slow-break variants can build up too much medicine and have worse side effects.
The authors say pharmacogenomic testing before prescribing could make use safer and more effective.
How this fits with other research
Hudson et al. (2012) already warned that only a few psychotropics have strong evidence in autism. Singh adds a new layer: even those few drugs may work differently depending on genetics.
Hoyle et al. (2022) found that most clinics rely on parent reports, not direct behavior data, when they judge if a med is helping. Singh’s gene-first angle does not clash, but it does shift the spotlight away from behavior checks and toward DNA.
Lemons et al. (2015) linked melatonin-pathway genes to sleep problems in autism. Singh widens the gene net to drug-metabolizing enzymes, extending the idea that genes can guide pediatric prescriptions.
Why it matters
If you work with kids who take risperidone, fluoxetine, or similar meds, you can now ask the prescriber if pharmacogenomic results are on file. Slow-metabolizer status can explain sudden sedation or new tics. Pair the gene report with your behavior data to time dose changes more safely.
Want CEUs on This Topic?
The ABA Clubhouse has 60+ free CEUs — live every Wednesday. Ethics, supervision & clinical topics.
Join Free →Check if the prescribing doc has pharmacogenomic results; if not, share Singh’s review and suggest testing before the next dose tweak.
02At a glance
03Original abstract
Psychotropic medication is commonly used for the treatment of mental health conditions. However, the genetic factors that influence psychotropic medication responses in children have not been thoroughly investigated. To address this gap, a systematic review and thematic analysis were conducted to examine the genetic impact of psychotropic medication response in children. The Down and Blacks and Consolidated Health Economic Evaluation Reporting Standards (CHEERS) checklists assessed the quality of studies and health economics, respectively. Using PRISMA reporting guidelines, 50 articles were identified with a sample size ranging from 2 to 2.9 million individuals. Most of the studies reported on ethnicity, and approximately half of the studies (24/50) were performed in North America. Five themes emerged from the thematic analysis: (1) implications of non-CYP450 polymorphisms, (2) paediatric CYP450 pharmacogenetics, (3) genetic predictors of response, (4) insights for implementation and future research and (5) phenoconversion. The thematic analysis revealed that assessment of non-CYP450 polymorphisms and psychotropic medication response, especially in those with mental health conditions such as autism, would be helpful. Epilepsy onset, risk and treatment response were associated with non-CYP450 genetic variants. Phenoconversion of substrates associated with CYP2D6 and CYP2C19 metabolisers is common in individuals with mental health conditions, and ABCB1 variants can influence psychotropic medication responses. A multidisciplinary model could also help guide clinical decision-making in cases involving complex neurodevelopmental profiles. Using the Down and Blacks checklist, the average score from the 50 studies was 17.7 points (min. 14, max. 24). The health economic evaluation of studies using the CHEERS checklist gave an average score of 33.0% (range: 21.4% to 35.7%). The study provides an important resource of information for healthcare professionals, researchers and policymakers working at the intersection of child psychiatry, pharmacogenomics and precision medicine.
Genes, 2025 · doi:10.3390/genes16091055